Denis Wirtz: MEK inhibitors have significant off-target toxicity and lack predictive biomarkers

Denis Wirtz, Vice Provost of Research at Johns Hopkins University, shared on X about recent paper by Paul M. Kuhn et al., titled “Local, Sustained, and Targeted Co-Delivery of MEK Inhibitor and Doxorubicin Inhibits Tumor Progression in E-Cadherin-Positive Breast Cancer” published on MDPI.

Authors: Paul M. Kuhn, Gabriella C. Russo, Ashleigh J. Crawford, Aditya Venkatraman, Nanlan Yang, Bartholomew A. Starich, Zachary Schneiderman, Pei-Hsun Wu, Thi Vo, Denis Wirtz and Efrosini Kokkoli

“MEK inhibitors have significant off-target toxicity and lack predictive biomarkers.

Here, we use a thermosensitive, biodegradable hydrogel with functionalized liposomes for sustained release of MEK inhibitors to E-cad-positive breast tumors.”

Source: Denis Wirtz/X